BGIM
TPST icon

Brandywine Global Investment Management’s Tempest Therapeutics TPST Stock Holding History

Brandywine Global Investment Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3
Closed -$45K – 993
2016
Q2 		$45K Hold
3
– – ﹤0.01% 828
2016
Q1 		$82K Hold
3
– – ﹤0.01% 800
2015
Q4 		$85K Buy
3
+1
+50% +$33K ﹤0.01% 777
2015
Q3 		$42K Buy
+2
New +$135K ﹤0.01% 858
2015
Q2 		– Hold
0
– – – 885

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Brandywine Global Investment Management's TPST Position: Q3 2016 in Review

Brandywine Global Investment Management sold out of Tempest Therapeutics (TPST) in Q3 2016, closing a stake of 3 shares — an estimated $45K sold.

Brandywine Global Investment Management first reported a position in TPST in Q3 2015 and held it in 4 quarters. The position peaked at $85K in Q4 2015. 80 funds tracked by Wall St. Rank hold TPST as of Q3 2016.

  • Brandywine Global Investment Management reported no remaining Tempest Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Brandywine Global Investment Management sold 3 Tempest Therapeutics shares in Q3 2016, an estimated $45K.
  • Brandywine Global Investment Management first reported a position in Tempest Therapeutics in Q3 2015 and held it in 4 quarters.
  • Brandywine Global Investment Management's Tempest Therapeutics position peaked at $85K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2016.

Based on Brandywine Global Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.